2024-03-29T04:47:02Zhttps://eprints.lib.hokudai.ac.jp/dspace-oai/requestoai:eprints.lib.hokudai.ac.jp:2115/625782022-11-17T02:08:08Zhdl_2115_64361hdl_2115_20040hdl_2115_64360hdl_2115_121Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer with PTV < 100 cc using a continual reassessment method (JCOG0702)Onimaru, RikiyaShirato, HirokiShibata, TaroHiraoka, MasahiroIshikura, SatoshiKarasawa, KatsuyukiMatsuo, YukinoriKokubo, MasakiShioyama, YoshiyukiMatsushita, HaruoIto, YoshinoriOnishi, HiroshiPhase I studyContinual reassessment methodNon-small cell lung cancer (NSCLC)Stereotactic body radiotherapySBRT490Purpose: To estimate the maximum tolerated dose (MTD) and to determine the recommended dose (RD) of stereotactic body radiation therapy (SBRT) for peripheral T2N0M0 non-small cell carcinoma (NSCLC) with target volume (PTV) < 100 cc. Materials and methods: The continual reassessment method (CRM) was used to determine the dose level that patients should be assigned to and to estimate the MTD. Dose limiting toxicity (DLT) was grade 3 radiation pneumonitis (RP) within 180 days after the start of SBRT, grade 2 RP was used as a surrogate DLT. The RD was equal to the MTD. The dose was prescribed at D95 of the PTV. Results: Fifteen patients were accrued. Only 1 experienced grade 2 RP at 60 Gy in 4 fractions. It was difficult to fulfill the dose constraints at 60 Gy in 4 fractions, and the maximum dose level assigned by CRM was changed to 55 Gy in 4 fractions. The lower limit of 95% of the credible interval exceeded the adjacent level, and the RD was determined as 55 Gy in 4 fractions. Conclusions: The RD of SBRT for peripheral T2N0M0 NSCLC with PTV < 100 cc was determined to be 55 Gy in 4 fractions.ElsevierJournal Articleapplication/pdfhttp://hdl.handle.net/2115/62578https://eprints.lib.hokudai.ac.jp/dspace/bitstream/2115/62578/1/manuscript%2bappendix.pdf0167-8140AA10476884Radiotherapy and oncology11622762802015-08enginfo:pmid/26233591info:doi/10.1016/j.radonc.2015.07.008© 2015, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/author